Search results
Results from the WOW.Com Content Network
Just in time for fall and winter sniffles, an advisory committee to the US Food and Drug Administration has decided that a popular ingredient in oral cold and allergy medications doesn’t work.
After an FDA advisory committee said the decongestant phenylephrine, an ingredient found in many oral cold and flu medications, is ineffective, experts weigh in on alternatives.
The FDA announced a proposal to remove oral phenylephrine, found in many popular OTC decongestants, from shelves. The reason for the ban is that the ingredient just isn’t effective, the FDA says.
These include for adults: antihistamines, antihistamine-decongestant combinations, benzonatate, anti asthmatic-expectorant-mucolytic combinations, expectorant-bronchodilator combinations, leukotriene inhibitors, ambroxol, and guaifenesin, sometimes with analgesics, antipyretics, anti inflammatories, and anticholinergics; and for children ...
A decongestant, or nasal decongestant, is a type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine (the latter of which has disputed effectiveness ).
[13] [2] Phenylephrine has replaced pseudoephedrine in many over-the-counter oral decongestant products. [2] However, oral phenylephrine appears to be ineffective as a decongestant. [ 31 ] [ 32 ] In 2022, the combination with brompheniramine and dextromethorphan was the 265th most commonly prescribed medication in the United States, with more ...
In adults and children age 2 and older, use it only on the neck and chest to ease coughing during a cold, per the Mayo Clinic. Vicks VapoRub is made of ingredients such as camphor, eucalyptus oil ...
Xylometazoline is in the decongestant and alpha-adrenergic agonist families of medication. [5] [6] One study classified it with selectivity ratios in alpha 2 adrenergic receptors of 151 for a2A vs a2B, 4.5 a2A vs a2C, and 33.9 a2B vs a2C. Making it a highly selective a2A agonist. [7] Xylometazoline was patented in 1956 and came into medical use ...